Ian Kalvinskas Pediatric Liver Cancer Early Detection and Screening Act

H.R. 5355, the Ian Kalvinskas Pediatric Liver Cancer Early Detection and Screening Act, was introduced in the House on September 15, 2025, by Rep. Costa (D-CA) and referred to the House Committee on Energy and Commerce. The bill directs the HHS Secretary to carry out activities promoting newborn liver disease screenings, specifically citing routine direct-bilirubin measurement in heel-stick blood spot panels. As of the latest action on September 18, 2025, the sponsor delivered introductory remarks. The bill remains in the earliest legislative phase—no hearings, no markups, no Senate companion, and no appropriated funding. The money trail is the critical fact here: this bill authorizes policy direction but contains no funding authorization numbers. Authorization without appropriation is a legislative statement, not a budget allocation. Any actual spending would require a separate appropriations bill, a Centers for Medicare & Medicaid Services (CMS) reimbursement determination, or state-level public health funding. The path from this bill to revenue for diagnostic companies requires at minimum: (1) committee markups and floor passage in the House, (2) Senate introduction and passage, (3) Presidential signature, (4) HHS rulemaking (typically 18-36 months), and (5) state adoption into standard newborn screening panels. That timeline, if it proceeds at all, extends years into the future. Structural beneficiaries if the bill were to eventually pass with funding include Thermo Fisher Scientific as a supplier of clinical chemistry analyzers and reagents, Quest Diagnostics and Labcorp as reference laboratory operators, and Illumina as a provider of confirmatory sequencing. However, the mechanism of action is tenuous: newborn screening in the U.S. is administered by state public health laboratories, not commercial labs. The bill text explicitly centers on 'direct-bilirubin measurement in the newborn heel-stick panel'—a low-cost, widely available chemistry test already performed in most hospital labs. The addressable volume increase for a commercial lab is minimal without a structural shift in state testing models. Real market data from April 2026 shows diagnostic stocks in a broad pullback: at $474.19 (-3.53% over 30 days), at $194.79 (-0.61% over 30 days), at $261.31 (-2.07% over 30 days), and at $125.90 (+2.14% over 30 days). The 30-day declines for , , and reflect broader market conditions, not legislative action on H.R. 5355. The 7-day changes are slightly negative for all but (+0.95%). There is no detectable price correlation with this bill. Remaining legislative steps: the bill has not yet been scheduled for a committee hearing. As a House-only bill with 10 cosponsors and a junior Democratic sponsor (Rep. Costa, not a committee chair), momentum is low. The 119th Congress spans 2025–2027, but to become law, this bill must navigate the House Energy and Commerce Committee, full House vote, Senate Health, Education, Labor and Pensions Committee, full Senate vote, and conference committee reconciliation—all before the 119th Congress adjourns.